Literature DB >> 8552862

Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis.

T Fujishima1, Y Honda, N Shijubo, H Takahashi, S Abe.   

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disease in which alveoli are filled with lipoproteinaceous materials. We measured carcinoembryonic antigen (CEA) concentrations in bronchoalveolar lavage (BAL) fluids and sera from patients with PAP and from healthy volunteers (HV). Significantly increased CEA values were found in BAL fluids and sera from patients with PAP compared with those from HV. BAL fluid CEA values significantly correlated to serum CEA values in patients with PAP. Serum CEA values significantly correlated to serum lactate dehydrogenase activity and alveolar-arterial PO2 difference values in patients with PAP. Successive measurements of serum CEA showed that serum CEA values reflect the disease activity of PAP. The determination of serum CEA is useful for evaluating disease severity of PAP.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8552862     DOI： 10.1159/000196473

Source DB:  PubMed          Journal:  Respiration        ISSN： 0025-7931            Impact factor:   3.580


  11 in total

Review 1.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.

Authors:  P L Shah; D Hansell; P R Lawson; K B Reid; C Morgan
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services.

Authors:  I Fukuda; M Yamakado; H Kiyose
Journal:  J Med Syst       Date:  1998-04       Impact factor: 4.460

3.  Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  Minkyu Jung; Se Hyun Kim; Young Joo Lee; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

4.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

5.  MUC1 gene polymorphisms are associated with serum KL-6 levels and pulmonary dysfunction in pulmonary alveolar proteinosis.

Authors:  Francesco Bonella; Xiaoping Long; Shinichiro Ohshimo; Yasushi Horimasu; Matthias Griese; Josune Guzman; Nobuoki Kohno; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2016-04-23       Impact factor: 4.123

6.  Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.

Authors:  Yuan Gao; PingPing Song; Hui Li; Hui Jia; BaiJiang Zhang
Journal:  BMC Cancer       Date:  2017-07-14       Impact factor: 4.430

7.  Assessment and management of pulmonary alveolar proteinosis in a reference center.

Authors:  Ilaria Campo; Francesca Mariani; Giuseppe Rodi; Elena Paracchini; Eric Tsana; Davide Piloni; Isabella Nobili; Zamir Kadija; Angelo Corsico; Isa Cerveri; Claudia Chalk; Bruce C Trapnell; Antonio Braschi; Carmine Tinelli; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2013-03-13       Impact factor: 4.123

8.  Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis.

Authors:  Francesco Bonella; Shinichiro Ohshimo; Cai Miaotian; Matthias Griese; Josune Guzman; Ulrich Costabel
Journal:  Orphanet J Rare Dis       Date:  2013-04-04       Impact factor: 4.123

9.  Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  Minkyu Jung; Se Hyun Kim; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

Review 10.  The Clinical Clues of Pulmonary Alveolar Proteinosis: A Report of 11 Cases and Literature Review.

Authors:  Qiongya Mo; Bingbin Wang; Nian Dong; Lianmin Bao; Xiaoqiong Su; Yuping Li; Chengshui Chen
Journal:  Can Respir J       Date:  2016-04-26       Impact factor: 2.409
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.